Hospital Shares Rise After Government Caps Cancer Drug Trade Margins at 30%

Shares of several major hospital chains in India saw notable gains on Friday following the government’s announcement to impose a 30% trade margin cap on non-scheduled anti-cancer drugs. This regulatory move aims to bring down the retail prices of numerous cancer medications by as much as 70%, potentially saving patients around Rs 2,500 crore each year.

The decision targets excessive mark-ups within the supply chain, seeking to make cancer treatment more affordable without disrupting the availability of life-saving medicines. It broadens the scope of an earlier policy which had capped margins only on select oncology drugs.

Among the hospital stocks benefiting from this development, Fortis Healthcare led with an over 5% increase, closing at Rs 805 per share. Dr Agarwal’s shares rose about 2% to Rs 478 on the Bombay Stock Exchange. Apollo Hospitals, Manipal Health, and Medanta experienced gains of 4%, 3.5%, and 3.1% respectively. Max Healthcare also advanced more than 4%, reaching Rs 915 per share.

Global investment bank Jefferies weighed in on the impact of the price cap on hospital operators, suggesting that while margins could face short-term pressure, the effect is likely to be temporary. The bank maintained a Buy rating for the sector, pointing out that regulatory uncertainties have eased for now.

Jefferies highlighted that consumables—such as medical devices and implants—make up roughly 12-15% of a patient’s hospital bill, but the margins on these items tend to be low due to prior price controls on high-value products like stents and implants since 2017. The government is reportedly in discussions with industry stakeholders to rationalize trade margins on these consumables as well.

While concerns remain about potential markups on consumables, Jefferies believes the overall earnings impact on hospitals’ EBITDA (earnings before interest, taxes, depreciation, and amortization) will be manageable. The brokerage drew parallels to the price caps on cardiac stents and orthopedic knee implants imposed nearly a decade ago, which led to a 70-85% price reduction. Hospitals then adjusted by gradually increasing procedure fees and streamlining costs over a year or so, successfully restoring profitability.

Apollo Hospitals applied a similar strategy in 2017-18, regaining its EBITDA margins within a few quarters after earlier regulatory interventions. Jefferies also noted that hospital stocks typically experience a period of volatility for three to six months following such regulatory changes before rebounding. For instance, Apollo Hospitals delivered a 3% return in the year after price caps were introduced on stents and implants.

The brokerage remains optimistic about the hospital sector’s long-term outlook, citing strong demand for quality tertiary care facilities. Following recent market corrections, hospital stocks are trading at lower valuations—around 21 to 25 times estimated FY28 EV/EBITDA multiples, compared to 25 to 35 times a year ago—presenting potential attractive investment opportunities for companies with sustainable earnings growth. Jefferies’ preferred stocks include Fortis, Manipal, Apollo Hospitals, Max Healthcare, and Medanta.

Emkay Research echoed a similar view, noting limited earnings impact for its healthcare coverage universe based on discussions with hospital chains. Pharmacies contribute around 15-20% of hospital revenue but have relatively modest margins of 20-25%. They pointed out that margin caps would mainly affect patients paying out of pocket, since those with insurance or public health coverage typically use negotiated package rates that are lower than standard retail prices. This dynamic may further cushion earnings effects for hospital operators.

Emkay does not foresee a broad-based margin cap on all drug categories due to the complexities in implementation across manufacturers, distributors, and supply chains. However, it acknowledged ongoing regulatory scrutiny in the sector given the sensitive socio-economic implications of healthcare pricing.

Emkay maintains positive ratings and target prices for several hospital stocks, including KIMS (Buy at Rs 850), Park (Buy at Rs 375), Medanta (Add at Rs 1,500), Max Healthcare (Add at Rs 1,150), and Rainbow (Add at Rs 1,550).

The government’s move to regulate trade margins on cancer drugs is part of a broader effort to make healthcare more affordable and accessible in India. Hospitals and investors will be closely watching how policy evolves, especially regarding consumables and other medical devices, as these factors will influence the sector’s financial performance and stock valuations in the months ahead.